Return to homepagePandemic Pact

Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

  • Funded by Swiss National Science Foundation (SNSF)
  • Total publications:0 publications

Grant number: 52533.1 IP-LS

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2021

  • Known Financial Commitments (USD)

    $1,331,387.03

  • Funder

    Swiss National Science Foundation (SNSF)

  • Principal Investigator

    Thomas Klimkait

  • Research Location

    Switzerland

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

RocketVax AG, a startup company from Basel, together with academic partners in Switzerland, will develop a next-generation vaccine against SARS-CoV-2. Based on a live, single-cycle virus, this vaccine will provide a broader and more durable protection, offering a superior and long-term solution.